Pharma-Bio Serv Reports 19% Revenue Growth in Third Quarter, Net Loss Improves

Pharma-Bio Serv, Inc. reported its financial results for the third quarter and nine months ended July 31, 2026, revealing a total revenue of $2.34 million for the quarter, an increase of approximately 19% from $1.96 million in the same period last year. For the nine-month period, revenues reached $7.33 million, up from $6.85 million in the prior year. The company experienced a gross profit of $691,734 for the quarter, compared to $574,262 in the previous year, reflecting a gross profit margin of 29.6%. However, the company reported a net loss of $14,219 for the quarter, an improvement from a loss of $204,250 in the same period last year, while net income for the nine months was $251,627, a significant recovery from a loss of $100,361 in the prior year.

The financial performance indicates a notable recovery in profitability, particularly in the Puerto Rico and European markets, which saw revenue increases of approximately $0.5 million and $0.1 million, respectively. However, the U.S. consulting market experienced a slight decline of $0.1 million. The company’s selling, general, and administrative expenses decreased to $763,546 for the quarter, down from $888,139 in the same period last year, primarily due to reduced occupancy costs and other planned savings.

Operationally, Pharma-Bio Serv continues to focus on its core business of compliance consulting services across various sectors, including pharmaceuticals and biotechnology. The company has maintained a steady customer base, with significant revenue contributions from a few key clients, which accounted for 49.1% of total revenues in the latest quarter. The company’s total assets decreased to $11.44 million as of July 31, 2026, down from $13.65 million at the end of the previous fiscal year, largely due to a reduction in cash and cash equivalents.

Looking ahead, Pharma-Bio Serv aims to expand its market presence in Puerto Rico, the United States, and Europe while exploring opportunities in Brazil. The company is also adapting to changing market conditions and regulatory environments, including potential impacts from recent tax legislation. Management believes that the current level of working capital and cash flows from operations will be sufficient to meet anticipated expenses and contractual commitments over the next twelve months. The company remains committed to enhancing its business development infrastructure to capitalize on new opportunities in the compliance consulting sector.